

GLOBAL ONCOLOGY -DREAM OR REALITY?

Prof. Dr Cristina Stefan MD, MMED, FCP, MSc, PhD, MBA Treating patients in Africa. The most disadvantaged human population on earth.





Doctor, I want you to cure me! African patients with advanced disease










Burkitt Lymphoma



Curable with appropriate and timely treatment despite late presentation and advanced disease.

Indolent, aggressive or highly aggressive tumor?







Structure

What is global oncology?

Cancer in Asia 2019

Dream or reality?

What is global oncology?



Common global health definition a decade ago- the Consortium of Universities for Global Health (>170 academic institutions and partners worldwide)

What is global oncology?



Substantial health disparities exist for cancer. In 2018, 59% of new cancer cases and 70% of cancer deaths occurred in low- and middleincome countries.



The recent emergence of global oncology as an academic discipline seeks to promote scientific and clinical advances for cancer worldwide



Global Oncology's mission is to bring the best in **cancer** care to underserved patients around the world. We collaborate across geographic, professional and academic borders to improve **cancer** care, research and education



ğ

~~

Global oncology as a real academic career path...

Multiple facets of the discipline of Global Oncology

Global oncology initiatives

Global oncology research

Global oncology trends

####

Practising across borders


Cancer in Asia 2019

Cervical Cancer

Cancer in Asia 2019

Childhood cancer

Asia follows most global trends for common types of cancers, with some key differences.




The most common male cancer in <u>Asia is lung cancer</u>, while in the West it is prostate cancer. For <u>Asian women, breast</u> <u>cancer is the most common</u>, but cervical and **liver** cancers occur more frequently than in other regions.



Even though cervical cancer has a long latency period and effective screening methods, more women die from it in Asia than in the West.






Think globally, act locally


The total population in East Asia is 1.486 billion, which accounted for 19.45% of the global population. In 2017, there were 2,731,480 (2,892,040–2,542,159) total deaths due to cancer in East Asia, accounting for 28.9% of the world's total number of deaths. Sep 12, 2019


Asia- the real overall cancer rate?











3

While cervical cancer has been decreasing in Thailand and India, breast cancer has been increasing and is now more common than cervical cancer.

TRENDS IN AGE-STANDARDIZED INCIDENCE RATES (WORLD) PER 100,000



Public Health Progress in Asia

• Communicable, maternal, perinatal and nutritional conditions

Cause of death	2000	2015	% change
Vaccine-preventable infections	309,000	82,000	↓ 73%


Cervical cancer

Even though cervical cancer has a long latency period and effective screening methods, more women die from it in Asia than in the West.

India alone accounts for 27% of global cervical cancer deaths, which may be due to the unavailability of screening




Cervical Cancer: A Prevention Success Story



WHO Calls for "A World Free of Cervical Cancer"

Proposed 2030 targets



The Ability to Eradicate Cervical Cancer is Here

With vaccination, access to screening & modern molecular tests...Australia is on track

Eliminating cervical cancer globally is within reach if governments act *Ian Frazer*

We have the unique opportunity to wipe out a cancer that kills 250,000 women worldwide each year

Australia's new cervical cancer test 'much more sensitive' - Cancer Council


Women will need the test for the human papillomavirus (HPV) every five years rather than a pap smear every two years

Australia could become first country to eradicate cervical cancer

Free vaccine program in schools leads to big drop in rates, although they remain high in the developing world

Source: https://www.theguardian.com/society/2019/jun/26/hpv-human-papilloma-virus-vaccine-cervical-cancer-elimination-study

HPV primary screening adoption across the globe: After years of scientific evidence, clinical practice has started to change



Program status for each country is updated with most current information available to Roche but may not reflect actual status

Cervical Cancer Screening Trends in Asia For countries as well as individuals, **no two cancer journeys** are the same. Malaysia China

CxCa incidence: 1682 per year CxCa mortality: 944 per year	CxCa incidence: 106430 per year CxCa mortality: 47739 per year
 Current situation: Screening method: Yearly Pap cytology for women age 20-65 yo. Since 1998~15% screening coverage) Vaccination: School based for 13 years old girl since 2010 (90% coverage) 	 Current situation: Screening method: Opportunistic screening done either with Pap Cytology, co-testing or HPV primary Vaccination: Out of pocket since 2018
 In progress: Screening method: HPV primary screening with self- collected samples in pilot sites 	 In progress: Exploring self-collected sample in rural and unscreened women
 Goal: Screening method: National wide roll out of HPV primary screening with self-collected samples by 2023 	 Goal: Screening method: National wide roll out of HPV primary screening in coming years Guidelines for primary HPV testing in Cervical cancer screening in Malaysia – updated 27th May 2019


Greater attention was placed on prevention and early detection compared to cancer treatment and care.



"You will find, as a general rule, that the constitutions and the habits of a people follow the nature of the land where they live." *Hippocrates (460-370 BCE); and hence, their cancers too...*



Cancers Due to Five Infections Correspond to 18% of Global Cancer Incidence



Infections cause about:

 18% of cancers globally
 (>2 million cases/year)


26% of cancers in LMICs

.

 40% of cancers in Africa

AAR American Association for Cancer Research

Liver Cancer Kills 1% of the World's Population



Cancer of the liver cause ~1% of all deaths worldwide (~100 deaths per million people per year) and 9% of all deaths from cancer.

In 2017, the World Health Assembly passed a resolution on cancer control which recommends that countries develop National Cancer Control Plans (NCCPs) to guide all cancer prevention and management activities

Progression of operational cancer plans worldwide per region

Region	2013	2017
Africa	46%	74%
Americas	61%	77%
Eastern Mediterranean	48%	71%
Europe	82%	90%
South-East Asia	73%	91%
Western Pacific	83%	83%
Total	66%	81%

Global Health Observatory data repository, <u>http://www.who.int/gho/en/</u>, Noncommunicable diseases > National capacity, Policies, strategies and action plans last update 2018-8-14.

Economist Intelligence Unit 2019 questionnaire on

level of

preparedness for the cancer epidemic across 28 countries

				High	(85.1 - 100)	M	odera	te (70.1 - 85)	Low	(50.1 - 70)		Very low (0 - 50)
OVERALL SCORE 1) POLICY & PLANNING		2) CARE DELIVERY			3) HEALTH SYSTEM & GOVERNANCE								
1	Australia	90.6	1	Australia	98.0		1	Japan	96.6	1	1	Sweden	86.7
2	Netherlands	89.9	2	UK	96.3		2	Netherlands	92.1	2	2	Netherlands	77.1
3	Germany	88.7	3	Brazil	94.4		3	Germany	91.8	3	3	Australia	76.9
4	France	87.5	=4	Canada	94.0		4	Australia	90.0	4	4	Germany	76.3
5	UK	85.3	=4	Netherlands	94.0		5	Spain	89.2	5	5	France	76.1
6	Canada	84.8	6	France	93.8		6	France	86.9	6	6	US	75.7
=7	Spain	84.0	7	Colombia	92.1		7	Sweden	85.6	7	7	UK	74.0
=7	US	84.0	8	Germany	91.8		8	Italy	84.7	8	3	Canada	71.5
9	Japan	83.2	9	Spain	89.7		9	US	84.2	g	9	South Korea	68.5
10	Sweden	82.5	10	US	88.0		10	Brazil	84.1	1	10	Spain	62.1
11	Brazil	82.2	11	Turkey	87.4		11	Colombia	83.6	1	11	Italy	58.1
12	South Korea	80.4	12	South Korea	86.7		12	Canada	82.2	1	12	Japan	56.7
13	Italy	79.9	13	Thailand	86.4		13	Chile	80.7	1	13	Chile	56.6
14	Colombia	79.8	14	Italy	85.9		=14	South Korea	80.0			AVERAGE	55.5
	AVERAGE	72.8	15	Argentina	83.4		=14	UK	80.0	1	14	Brazil	54.1
15	Argentina	71.7	16	Japan	83.1		16	Argentina	73.7	1	15	China	53.7
16	Chile	69.9		AVERAGE	81.3			AVERAGE	73.0	1	16	South Africa	48.2
17	Thailand	69.4	17	India	80.8		17	Russia	72.9	1	17	Colombia	47.5
18	Turkey	65.5	18	Kenya	77.6		18	Thailand	64.4	1	18	Turkey	47.4
19	India	64.9	19	Sweden	77.3		19	Mexico	61.9	1	19	Romania	46.5
20	China	64.5	20	Mexico	73.2		=20	China	61.3	2	20	Thailand	45.4
21	Russia	63.4	21	China	73.1		=20	India	61.3	2	21	Mexico	45.2
22	Mexico	63.1	22	South Africa	72.2		22	South Africa	56.7	2	22	Argentina	44.1
23	South Africa	61.2	23	Egypt	66.2		23	Indonesia	56.6	2	23	Indonesia	43.6
24	Kenya	55.5	24	Chile	65.8		24	Saudi Arabia	54.0	2	24	Russia	41.1
25	Indonesia	55.1	25	Russia	64.9		25	Turkey	52.6	2	25	India	40.3
26	Saudi Arabia	53.0	26	Saudi Arabia	62.6		26	Kenya	46.5	2	26	Saudi Arabia	32.0
27	Romania	51.1	=27	Indonesia	59.4		27	Egypt	45.1	2	27	Kenya	29.2
28	Egypt	48.4	=27	Romania	59.4		28	Romania	45.0	2	28	Egypt	19.7

Note. Normalised scores 0-100, where 100=most prepared. Source: ICP.

Asian countries investigated are highlighted in orange

Cancer in Asia 2019

Childhood cancer

WHO Global Initiative for Childhood Cancer




Outline: Childhood Cancer

- Why now for a Global Initiative?
- Background & current status of Initiative
- Translating Global Initiative into lives saved



Why Lack of Progress in Cancer?



Must be in core package of services to realize UHC

Childhood Cancer as Priority Investment

Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition

Hellen Gelband, Rengaswamy Sankaranaryonana, Cindy L Gauvreus, Suran Hotna, Benjamin O Anderson, Freddel Bray, James Clemy, Anna J Dare, Lynette Denny, Mary K Gaspodarowicz, Samit Gupta, Scott C Howard, David A Jaffray, Felicia Knaul, Carol Levin, Linda Rabeneck, Pretha Rajaramar, Terrence Sulfware, Edward L Trinhibe, Probhat Jin, for the Diasese Control Montifies-3 Concer Author Goup*

Table 1.5 Approximate Per Capita Marginal Costs of the Essential Package for Low-Income, Lower-Middle-Income, and Upper-Middle-Income Countries

(2012 U.S. dollars)


Intervention	Low- income	Lower-middle- Income	Upper-middle- income
Comprehensive tobacco control measures	0.05	0.07	1.06
Palliative care and pain control	0.05	0.06	0.06
HBV vaccination	0.08	0.04	0.04
Promote early diagnosis and treat early-stage breast cancer	0.43	0.43	1.29
HPV vaccination	0.23	0.23	0.40
Screen and treat precancerous lesions and early-stage cervical cancer	0.26	0.29	0.87
Treat selected childhood cancers	0.03	0.03	0.09
Subtotal	1.13	1.15	3.81
Ancillary services (50% of subtotal)	0.57	0.58	1.91
TOTAL COSTS	1.70	1.73	5.72

Source: Based on online annex 1A and Horton and Gauvreau 2015, annex 16A.

Note: HPV = human papillomavirus; HBV = hepatitis B virus.

Measuring Progress & Setting Priorities

Six of the Most Common Cancers in Children



Preliminary Country Selection

- **AFRO** (Africa): 2-3 preliminarily planned (tbc)
- EMRO (Eastern Mediterranean): to be confirmed
- EURO (Europe): Commonwealth of Independent States (CIS) to be confirmed
- **PAHO** (Americas): Peru, *Caribbean (tbc)*
- **SEARO** (Southeast Asia): Myanmar
- WPRO (Western Pacific): to be confirmed

WHO meeting



>60 working group meetings >200 documents shared > 50 countries involved >300 participants

Impact on countries already stated



"Lessons from Myanmar"

A Health Systems Approach for Strategic Planning and Action

From Prof Aye Aye Khaing Yangon Children Hospital

Haemato-oncology in Yangon Children Hospital, Myanmar



Anticipated new childhood malignancy cases 1800 to 2500 per year

Myanmar is the second largest countryin Southeast Asia with an estimated total population 59.13 million,U5 MR 52

2 PHO Centers 6 Paediatric hematooncologists





Aye Aye Khaing Professor MBBS,MMed Sc(Paed),MRCPCH, Dr Med (Pead) Paediatric Hemato Oncology Unit Vice-President – Myanmar Society of Haematology

Childhood Cancer Needs Assessment Myanmar


	HELPFUL: To Achieving the Objective	HARMFUL: To Achieving the Objective	
	STRENGTHS	WEAKNESSES	
INTERNAL ORIGIN: Attributes of orognization	 Dedicated team Continuous education locally and online Relationship with committed mentors ie, World Child Cancer, St Jude, Dana Farber Main tertiary and referral center 	 Manpower: low doctor:patient & nurse:patient ratio Diagnostics capabilities & facilities (pathology) Treatment i.e., complex pediatric oncologic surgery; long RT waiting list, visceral RT not feasible Lack of medical record database leading to difficulties summarizing cases and outcomes 	
EXIERNAL ORGN: Attributes of environment	 Well-networked blood donors group Local donors and fund raising MoH engaged/ adult cancer control efforts Funding (WCC, C2C, St. Jude) for training for MD and nurses, stipend supplements for support team OPPORTUNITIES 	 Wide geographical coverage High abandonment rate (mostly burden of secondary costs of treatment, need for family housing) Recruitment of human resources challenging Lack of comprehensive diagnostics facilities (Nat'l) THREATS 	

Why focus on childhood cancer in Myanmar?

- ✦ Childhood cancer is highly curable 80% can be cured
 - ✦ Common diagnoses include leukaemia, lymphoma, retinoblastoma
- ✦ Effective therapies for childhood cancers are known, and essential medications can be obtained
- Distinct considerations & competencies to optimally serve needs of children and families
- With focussed attention to childhood cancer within the overall cancer control programme, coverage and quality of care can be expanded

There can be no keener revelation of a society's soul than the way in which it treats its children. ~ Nelson Mandela


Health System Building Blocks Adapted for Childhood Cancer Control Planning





Outcome of Acute Lymphoblastic Leukaemia in Yangon Children Hospital

<u>Tint Myo Hnin</u>¹, Htike Tint Tun¹, Aung Kyaw Hein¹, Khin Nwe Oo¹, Yin Myat Thu¹, Ei Ei Shwe², Ei Phyo Win² and Aye Aye Khaing¹



CONCLUSION: Being one of the target centers of childhood cancer initiative program, strategies to reduce the treatment abandonment and to improve the supportive care including treatment related mortalities are underway to improve the outcome of childhood ALL.



Network

Dedicated Pediatric Hematology/Oncology <u>**Units:**</u>

- 300-bedded Mandalay Children Hospital
- Yangon Children Hospital

Shared Care Network Sites equipped to facilitate initial work-up or follow-up for children on treatment closer to home:

- North Okkalapa General Hospital (Yangon)
- Yankin Children Hospital (Yangon)
- Taunggyi Women and Children Hospital

Community Network Sites with engaged staff familiar with facilitating timely referrals to dedicated units / shared care sites:

- Bogale
- Hinthada
- Magway
- Maubin
- Mawlamyine General Hospital
 - Sitt
- Meikhtile
- 200-beded Women and Children Hospital (Monywa)
- Myaungmya

Helping children in Myanmar overcome cancer

Pyit Tine Htaung (Burmese Name of Doll Pictured) To my beloved little girl I will sing a lovely song of "Pyit Tine Htaung" Come and listen to me This will make you happy

The little Pyit Tine Htaung is short But he wears so lovely sweet smile Whenever he is thrown away He can stand again and again He never falls down

His life and his strong mind is so amazing He has no hands or legs But he can do everything Whenever he has difficulties He can face these and solve the problems with strong mind He never surrender the difficulties He tries to **overcome** these Finally he wins everything

My beloved little girl "Do you want to compete in running race with htm?"

Myanmar National Childhood Cancer Network



A Professional Network to Facilitate Communication, Coordination, and Advocacy to Increase Access and Strengthen National Delivery of Quality Care for Children with Cancer in Myanmar under the Auspices of the Myanmar Pediatric Society within the Myanmar Medical Association and Approved by the Ministry of Health and Sports of Myanmar

PatheinPyaponSittwe

• Myingyan

Naypyitaw

• Pakokku General Hospital

Global oncology: Dream or reality?


Dream or reality?

- Global oncology: what is and what is not about?
- A world where cancer is prevented or cured and every patient has the same chance
- Measuring impact
- How do we measure success?



Global oncology

A world where cancer is prevented or cured and every patient has the same chance for the best treatment and survivorship



Why global oncology?

A world-wide growth of cancer incidence: "the cancer epidemic" Most of the cancers will appear in low- and middle-income countries, where most of the population lives

A global coordinated approach is needed to support the effort of controlling cancer

Why global oncology?

- This support consists of:
 - Influx of funds, equipment, medicines and know-how from high-income countries
 - Training of oncologists, surgeons, pathologists and nurses to enable them to fight cancer successfully
 - Funding cancer research in collaborative projects and training researchers in lower income countries
 - Support awareness initiatives and advocacy for political action to control cancer
 - Identifying optimal local or regional solutions for specific cancer control problems, which could be successfully applied elsewhere.
 - Developing NCCPs and monitoring the incidence of malignant disease, as well as the progress in controlling it

Why global oncology?

- The efficient drawing of programmes and distribution of funding from international organizations and donors needs to be guided by research of the global reality of the growth of malignant disease.
- The discipline of global oncology developed out of the need to:
 - Conduct research to obtain the necessary knowledge about the global cancer situation
 - Create a repository of knowledge accessible to governments, to international organizations and to scientists
 - Facilitate the exchange of information, solutions and monitor the evolution of the cancer epidemic
 - Create a body of specialists who would contribute through their global perspective to the optimal coordination of efforts for cancer control

Global oncology

- Awareness, understanding and planning-VISION
- Willingness to act collaboratively
- Task force: ASCO global oncology: innovative research, quality improvement, and professional development
- Recognition as a discipline
- Identification of the needs
- Global fund for global cancer

Progress Depends on Collaboration

Global oncology training Global oncology research and practice Global oncology career Global oncology mentoring Global oncology innovation

CRISTINASTEFAN10@GMAIL.COM

